The most common docetaxel-based chemotherapy regimens and their use in patients with castration-resistant prostate cancer were studied. The study included 68 patients. The choice of a docetaxel-based chemotherapy regimen and its duration were determined by an attending doctor. Effectiveness was evaluated from PSA response (in patients with a pretreatment marker concentration of less than 20 ng/mg), changes in the WHO pain syndrome index (in view of the use of bisphosphonates), and objective therapeutic effect (if any measurable foci). Safety profile was described using the incidence and type of adverse reactions, including underlying disease-characteristic vital signs (weight and heart rate), and the laboratory toxicity criteria NCl-CTC. The investigators mainly used a conventional regimen containing docetaxel and prednisolone. In this study, Grade III-IV neutropenia was observed only in one patient (in three different cycles), there was no case of febrile neutropenia; toxicity plays no significant role in treatment delay. There was a reduction in pain syndrome in patients treated and untreated with bisphosphonates; this effect was more pronounced in those taking bisphosphonates. According to the measurable foci, there was a complete effect in 4 (5.9%), a partial effect in 26 (38.2%), disease stabilization in 18 (26.5%), and disease progression in 12 (17.6%) patients. Analysis of the register's materials provided encouraging results on the safety profile of docetaxel-based regimens for metastatic castration-resistant prostate cancer and revealed the state-of-the-art in Russian regions.